Mitochondrial control of fuel switching via carnitine biosynthesis
Christopher Auger, Hiroshi Nishida, Bo Yuan, Guilherme Martins Silva, Masanori Fujimoto, Mark Li et al. · 2026 · 7 citationsRead the paper
Environmental adaptation often involves a shift in energy utilization toward mitochondrial fatty acid oxidation, which requires carnitine. Besides dietary sources of animal origin, carnitine biosynthesis from trimethyllysine (TML) is essential, particularly for those who consume plant-based diets; however, its molecular regulation and physiological role remain elusive. Here, we identify SLC25A45 as a mitochondrial TML carrier that controls carnitine biosynthesis and fuel switching. SLC25A45 deficiency decreased the carnitine pool and impaired mitochondrial fatty acid oxidation, shifting reliance to carbohydrate metabolism. Slc25a45 -deficient mice were cold-intolerant and resistant to lipid mobilization by glucagon-like peptide-1 receptor agonist (GLP-1RA), rendering them resistant to adipose tissue loss. Our study suggests that mitochondria serve as a regulatory checkpoint in fuel switching, with implications for metabolic adaptation and the efficacy of GLP-1RA–based anti-obesity therapy.
3 ideas Seedlabs derived from this research
A diagnostic blood test measuring SLC25A45 mutation status and methylated amino acid levels to predict patient response to GLP-1 receptor agonist weight-loss drugs. The panel identifies metabolic bottlenecks in carnitine biosynthesis that may hinder lipid mobilization.
AI score 96/100A diagnostic test to identify patients who are likely to be resistant to GLP-1 receptor agonist (GLP-1RA) weight-loss drugs based on SLC25A45 genetic variants or expression levels.
AI score 88/100A companion diagnostic that uses SLC25A45 genetic variants and plasma trimethyllysine-to-carnitine ratios to predict whether a patient will lose adipose tissue on GLP-1 receptor agonist therapy (e.g., semaglutide, tirzepatide) before expensive treatment begins.
AI score 65/100